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Saving lives by treating epilepsy in
developing countries
An increased risk of premature death associated with epi-
lepsy is well known. Recent reports have documented an
even higher risk of premature mortality among people
with epilepsy living in low- andmiddle-income countries
(LAMICs).1 The epidemiology of epilepsy-associated
mortality in LAMICs is of great relevance, as more than
85% of those with epilepsy live in resource-limited coun-
tries.2 Not only is the risk of premature mortality higher
in LAMICs, but a greater proportion of deaths in these
regions are epilepsy-related (e.g., falls, burns, drowning,
and status epilepticus).1
The burden of epilepsy in LAMICs is extensive and
partly driven by stigma that contributes to the treatment
gap in these regions.2 Regrettably, the treatment gap is
more than 75% in low-income countries and more than
50% in most lower-middle- and upper-middle-income
countries, compared to gaps of less than 10% in most
high-income countries.3 The evidence is sufficiently
compelling to suggest that reducing the treatment gap
should reduce premature mortality in those with epilepsy
in LAMICs.
In the current issue ofNeurology®, Ngugi et al.4 report
on premature death among a large cohort of people with
active convulsive epilepsy (ACE) in rural Kenya followed
up for 3 years with regular visits. This population-based
cohort study included 754 persons with ACE and
231,410 without ACE, although there was some degree
of attrition (18% for those with and 32% for those with-
out ACE). Causes of mortality were assessed using the
World Health Organization (WHO) verbal autopsy tool
within 1–4 months of death. The WHO verbal autopsy
tool is a standardized questionnaire that is administered to
next of kin or caregivers to assess cause of death.
The authors reported a staggering mortality rate of
33.3/1,000 person-years for those with ACE compared
to a rate of 6.1/1,000 person-years for those without
ACE, with a standardized mortality ratio of 6.5, slightly
higher than that previously reported in a similar study
in rural China.5 Factors associated with premature mor-
tality included nonadherence to antiepileptic drugs,
cognitive impairment, and age older than 50 years.
As the authors suggested, the association between
cognitive impairment and premature mortality among
those with ACE is probably due to confounding and
not a true causal relationship because cognitive impair-
ment may be a marker for severe epileptic encephalo-
pathies (e.g., Lennox-Gastaut syndrome) that are
associated with high mortality rate.6
Perhaps the most important finding is that more than
half of all deaths were directly related to epilepsy, with
status epilepticus representing the most frequent “pre-
sumed” cause of death (38% of cases). Many of these
deaths probably could have been prevented with basic
medical management of seizures and status epilepticus.
This finding is in contrast to another carefully designed
prospective cohort study of the long-term risk of prema-
ture mortality in people with epilepsy in the UK, where
few people died from epilepsy-related causes.7 In the UK
study, death certificates, which are known to be fraught
with their own limitations, were used to determine cause
of death. In the Kenya study, verbal autopsy reports were
used, which could in part explain some of the discordant
findings between these 2 studies.
Despite the many strengths of this carefully designed
study by Ngugi et al., there are some limitations that
must be considered, all of which were carefully discussed
by the study authors. First, only patients with ACE were
examined. This selection bias is important because con-
vulsive seizures, particularly if frequent, are associated
with higher mortality.8 Second, the inclusion of only
patients who had a seizure in the past year probably
resulted in a cohort with more severe epilepsy. In gen-
eral, a person is classified as having active epilepsy when
he or she has experienced a seizure in the past 2 or 5
years, although a 1-year period may be acceptable in
some settings.9 Another issue that must be acknowl-
edged is that the authors used an ACE prevalence cohort
rather than also including those with incident epilepsy.
This study limitation likely underestimated premature
mortality in those with ACE, as mortality is higher dur-
ing the first year after diagnosis.8 Other limiting factors
included the lack of information regarding epilepsy syn-
dromes, epilepsy seizure types (beyond convulsive), and
cause of death in the general population. Finally and
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most importantly was the lack of postmortem examina-
tions, which is not unique to this otherwise carefully
designed study but rather is a limiting factor in most
resource-poor settings. Despite these limitations, the
authors should be applauded for their careful methodo-
logic approach to this important study.
What can we now say with certainty? Inadequate
treatment of epilepsy kills large numbers of people in
developing countries, and many of these deaths are pre-
ventable. A recent study found that the treatment gap in
Kilifi, Kenya was 62.4%.10 If we appropriately diagnose
and treat most people with epilepsy in LAMICs,
epilepsy-related premature death can be prevented. We
know enough now to take action and save lives. Our
primary objective should be to make preventing death
due to inadequate epilepsy treatment a public health
priority—framing epilepsy-associated death as a problem
that can be solved by appropriate access to diagnosis
and treatment and seriously pursuing implementation
research in this important area. In 2011 the WHO’s
Mental Health Gap Action Programme published
evidence-based guidelines for use in LAMICs.11 Imple-
mentation of these guidelines requires local adaptation
but represents the first step in guiding care in resource-
limited settings. There is no doubt that “the challenges
to these important processes are substantial,”11 but if
neurologists around the world grasp the opportunity to
save lives by the many thousands through simple diag-
nosis and treatment of epilepsy, we can end these sense-
less deaths.
AUTHOR CONTRIBUTIONS
Dr. Jette drafted and edited the manuscript. Dr. Trevathan edited and
contributed to writing of the final manuscript.
STUDY FUNDING
No targeted funding reported.
DISCLOSURE
N. Jette holds a salary award from Alberta Innovates Health Solutions
and a Canada Research Chair in Neuroscience Health Services
Research. She currently holds grants/research support from the Cana-
dian Institutes of Health Research, Alberta Innovates Health Solutions,
Alberta Health Services, the University of Calgary Faculty of Medicine
and Hotchkiss Brain Institute, and Alberta Health and Wellness. She
has no commercial financial disclosures. All grants and research support
are paid directly to the University of Calgary. E. Trevathan reports no
disclosures relevant to the manuscript. Go to Neurology.org for full
disclosures.
REFERENCES
1. Diop AG, Hesdorffer DC, Logroscino G, Hauser HA.
Epilepsy and mortality in Africa: a review of the literature.
Epilepsia 2005;46(suppl 11):33–35.
2. Newton CR, Garcia HH. Epilepsy in poor regions of the
world. The Lancet 2012;380:1193–1201.
3. Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global
disparities in the epilepsy treatment gap: a systematic
review. Bull World Health Organ 2010;88:260–266.
4. Ngugi AK, Bottomley C, Fegan G, et al. Premature mor-
tality in active convulsive epilepsy in rural Kenya: causes
and associated factors. Neurology 2014;82:582–589.
5. Mu J, Liu L, Zhang Q, et al. Causes of death among
people with convulsive epilepsy in rural West China: a
prospective study. Neurology 2011;77:132–137.
6. Autry A, Trevathan E, Van Naarden Braun K, Yeargin-
Allsopp M. Increased risk of death among children with
Lennox-Gastaut syndrome and infantile spasms. J Child
Neurol 2010;25:441–447.
7. Neligan A, Bell GS, Johnson AL, et al. The long-term risk
of premature mortality in people with epilepsy. Brain
2011;134:388–395.
8. Forsgren L, Hauser WA, Olafsson E, et al. Mortality of
epilepsy in developed countries: a review. Epilepsia 2005;
46(suppl 11):18–27.
9. Thurman DJ, Beghi E, Begley CE, et al. Standards for
epidemiologic studies and surveillance of epilepsy. Epilep-
sia 2011;52(suppl 7):2–26.
10. Mbuba CK, Ngugi AK, Fegan G, et al. Risk factors
associated with the epilepsy treatment gap in Kilifi,
Kenya: a cross-sectional study. Lancet Neurol 2012;
11:688–696.
11. Katchanov J, Birbeck GL. Epilepsy care guidelines for
low- and middle-income countries: from WHO men-
tal health GAP to national programs. BMC Med 2012;
10:107.
Neurology 82 February 18, 2014 553
